RAPT Therapeutics Inc

RAPT Therapeutics — Investor Presentation (January 2026)

28 slides from RAPT Therapeutics's investor presentation, Jan 14, 2026

  1. Slide 1: The Science to Overcome Inflammation – Corporate Presentation

    THE SCIENCE TO OVERCOME INFLAMMATION CORPORATE PRESENTATION JANUARY 2026

  2. Slide 2: Disclaimer

    Disclaimer Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the development of ozureprubart (RPT904), including the expected timing of clinical trials and the a

  3. Slide 3: RAPT Therapeutics is Developing Transformative Therapies for High-Value Inflammatory Diseases

    RAPT Therapeutics is Developing Transformative Therapies for High-Value Inflammatory Diseases Ozureprubart (RPT904) is a novel next-generation omalizumab bio-better anti-IgE antibody designed for less frequent dosing and greater compliance and potential for broader efficacy than omalizumab Potential

  4. Slide 4: RAPT Accomplishments and Milestones Fueled Momentum in 2025

    RAPT Accomplishments and Milestones Fueled Momentum in 2025 Clinical Development Received FDA clearance for IND for ozureprubart and initiated Phase 2b clinical trial in food allergy Reported positive Phase 2 data in CSU (Jeyou) supporting 16-week durability and best-in-class profile Organizational

  5. Slide 5: RAPT Therapeutics Pipeline

    INFLAMMATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 OZUREPRUBART (RPT904) Anti-IgE omalizumab bio-better Next Gen. CCR4 antagonist RAPT Therapeutics Pipeline ONCOLOGY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 TIVUMECIRNON CCR4 antagonist * GASTRIC, NSCLC ASTHMA (China) CSU (China) FOOD ALLERGY CSU # # RAPT o

  6. Slide 6: Ozureprubart Potential to Transform the Treatment of Allergic Diseases

    Ozureprubart Potential to Transform the Treatment of Allergic Diseases

  7. Slide 7: IgE is Key Driver of Allergic Reactions

    SENSITIZATION PHASE EFFECTOR PHASE IgE is Key Driver of Allergic Reactions Allergen is first introduced – Immune response is initiated Captures allergen, presents it to T cells Promotes B cell development Produces IgE antibodies Th2 Cell B Cell/ Plasma Cell APC ALLERGIC REACTION Food Allergy Chronic

  8. Slide 8: Omalizumab is Highly Effective in Reducing Allergic Reactions to Multiple Food Allergens

    Omalizumab is Highly Effective in Reducing Allergic Reactions to Multiple Food Allergens Leading to a Broad Label OUtMATCH: Wood et al. NEJM 2024 Dosing at Q2W or Q4W based on the FA dosing table Primary End Point Key secondary End Points other secondary End Points Difference, 60 (95% CI, 47 to 70)

  9. Slide 9: Omalizumab is Highly Effective in Chronic Spontaneous Urticaria and is Standard of Care

    Omalizumab is Highly Effective in Chronic Spontaneous Urticaria and is Standard of Care Results not from head-to-head trials; no direct comparisons can be made. Omalizumab 300 mg Q4W REMIBRUTINIB 25 mg BID DUPILUMAB 300 mg Q2W -11.3 -5.0 -6.3 -7.9 -6.8 -13.4 -12.6 REMIX-1 REMIX-2 RILZABRUTINIB 400 m

  10. Slide 10: Ozureprubart is a Next Generation anti-IgE Bio-Better Antibody with Several Potential Advantages

    Potential Attributes OZU OMA Frequency of treatment Q8/12W Q2/4W Injections per year 4-6 13-26 Available to high IgE and/or high weight FA patients (~25%) YES NO Limit need for up-dosing in CSU patients (20-30%) YES NO Simplified dosing table YES NO Ozureprubart is a Next Generation anti-IgE Bio-Bet

  11. Slide 11: Potential Advantages vs Omalizumab Support First Choice Positioning and Premium Pricing

    Potential Advantages vs Omalizumab Ozureprubart Advantages Support First Choice Positioning and Premium Pricing 1Based on primary market research n=45 payers, Nov 2024 ; Directors of Pharmacy n=7 in-depth interviews, June 2024; Payers n=5 in-depth interviews, June 2025 Well Positioned to Be First Ch

  12. Slide 12: Ozureprubart in Food Allergy

    Ozureprubart in Food Allergy Addressing high unmet needs as the potential preferred food allergy therapy

  13. Slide 13: Enormous Underserved Population of Food Allergy Patients in the US

    Enormous Underserved Population of Food Allergy Patients in the US 1Datamonitor, US, 2025 (Atopic Dermatitis, Psoriasis, Rheumatoid Arthritis), Roche Pharma Day 2025 (Food Allergy); 2Food Allergy Facts and Statistics for the US, FARE, April 2024 Patient numbers Food Allergy is an Epidemic with Serio

  14. Slide 14: Omalizumab Provides a Much-Needed Option for Food Allergy Patients

    OUTMATCH Phase 3 Study Omalizumab Provides a Much-Needed Option for Food Allergy Patients Addresses multiple allergens Good tolerability and safety record Subcutaneous injections Better tolerated than OIT with similar efficacy Addresses only a single allergen Burdensome titration Adverse events redu

  15. Slide 15: Very Rapid Omalizumab Launch in Food Allergy Underscores High Unmet Need

    Very Rapid Omalizumab Launch in Food Allergy Underscores High Unmet Need and Expands the Market for Ozureprubart Source: PharmaIntelligence epidemiology * Roche Q3 ‘25 Earnings Atopic Dermatitis Plaque Psoriasis Food Allergy Number of Patients PATIENT VOLUME (US) Year 1 Year 2 Year 3 Year 4 Year 5 Y

  16. Slide 16: Ozureprubart Projected to Dose Primarily at Q12W and Treat Patients Excluded from Omalizumab Label

    Ozureprubart Projected to Dose Primarily at Q12W and to Treat Patients Excluded from the Omalizumab Label for Food Allergy 8 dose strengths; 2 frequencies Q2 or Q4W (13 different regimens) ~25% of FA patients excluded from label due to high IgE/weight APPROVED OMALIZUMAB FOOD ALLERGY DOSING TABLE 3

  17. Slide 17: prestIgE: Ozureprubart Food Allergy Phase 2b Trial

    prestIgE: Ozureprubart Food Allergy Phase 2b Trial Primary Endpoint: Prespecified threshold by oral food challenge N=100 (2:2:1 Q12W, Q8W regimens and placebo) US/Canada/Australia clinical sites Topline data expected 1H 2027 24-Week Treatment Extension and Placebo Crossover Ozureprubart Q12W regimen

  18. Slide 18: Trial Populations and Powering Assumptions in prestIgE

    Trial Populations and Powering Assumptions in prestIgE N=75 Omalizumab-eligible N=25+ Omalizumab-ineligible Primary Analysis Population Powered to detect a 50% effect size at 90% confidence Goal: demonstrate statistically significant efficacy on par with omalizumab Exploratory Subpopulation Not powe

  19. Slide 19: Ozureprubart in CSU

    Ozureprubart in CSU Potential to become the preferred advanced therapy in patients with CSU

  20. Slide 20: Summary of Ozureprubart Phase 2 Results in CSU

    Summary of Ozureprubart Phase 2 Results in CSU Ozureprubart at both Q8W and Q12W dosing showed comparable efficacy and safety to omalizumab at Q4W dosing Both ozureprubart arms showed numerically superior efficacy to omalizumab arm on UAS7 and UAS7=0 (complete response) across all timepoints* Sustai

  21. Slide 21: CSU Phase 2 Trial Design (Jeyou)

    CSU Phase 2 Trial Design (Jeyou) Primary Endpoint: Change from baseline in UAS7 at Week 8, 12, 16 Secondary: UAS7=0, ISS7, HSS7, AAS7, DLQI at Week 8, 12, 16 N=135 (1:1:1), 45 per arm China sites 16-Week Follow Up Ozureprubart 300 mg Q12W (N=45) Ozureprubart 300 mg Q8W (N=45) Omalizumab 300 mg Q4W (

  22. Slide 22: Subject Disposition

    Subject Disposition 187 Screened Omalizumab Q4W N=45 Completed Week 16 43 (95.6%) N=137 Randomized Ozureprubart Q8W N=46 3 (6.5%) discontinued 1 Withdrawal of Consent 1 Non-compliance 1 Personal Reason 2 (4.4%) discontinued 0 Withdrawal of Consent 1 Non-compliance 1 Insufficient Efficacy Completed W

  23. Slide 23: Key Demographics and Baseline Characteristics

    Key Demographics and Baseline Characteristics * Discontinuation of omalizumab for non-efficacy reasons only. Minimum 4-month washout period (prior to Screening) Characteristics OZU Q8W (N = 46) OZU Q12W (N = 46) OMA Q4W (N = 45) Age (years) – Mean (SD) 41.5 (13.3) 40.2 (13.6) 38.0 (12.8) Female, n (

  24. Slide 24: Primary Endpoint: Change from Baseline in UAS7

    Primary Endpoint: Change from Baseline in UAS7 * Estimated based on the MMRM model, using the change from baseline in UAS7 values as the dependent variable, the baseline UAS7 score as the covariate, and randomization stratification factors (prior use of omalizumab or other biologic agents used for C

  25. Slide 25: Secondary Endpoint: Proportion of Subjects with UAS7=0

    Secondary Endpoint: Proportion of Subjects with UAS7=0 (“Complete Response”) * Proportion of UAS7=0 subjects using LOCF-filled outcomes with CMH chi-square test for stratification (prior use of omalizumab or other biologics used in CSU). % Subjects with UAS7=0 Weeks

  26. Slide 26: Safety Summary

    Safety Summary † AESI: Grade 5 allergic reactions according to the WAO Grading System for Systemic Allergic Reaction n (%) Patients OZU Q8W (N = 46) OZU Q12W (N = 46) OMA Q4W (N = 45) Any TEAE 31 (67.4) 33 (71.7) 29 (64.4) Treatment-related 13 (28.3) 12 (26.1) 10 (22.2) Treatment-related Serious TEA

  27. Slide 27: Ozureprubart Clinical Development Overview and Anticipated Milestones

    1H 2026 2H 2026 1H 2027 2H 2027 FA Phase 2b N=100 Topline Data CSU Phase 3 Start Ozureprubart Clinical Development Overview and Anticipated Milestones Phase 2 Asthma Data N=60 Phase 3 CSU Start Phase 3 Asthma Start CSU PK/PD Data

  28. Slide 28: Thank You

    Thank You Please visit www.rapt.com

RAPT Therapeutics — Investor Presentation (January 2026) on 6ix